KCM
REGN icon

Karp Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Karp Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50
Closed -$23K – 243
2015
Q3 		$23K Hold
50
– – 0.02% 221
2015
Q2 		$26K Buy
+50
New +$24.4K 0.02% 222

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Karp Capital Management's REGN Position: Q4 2015 in Review

Karp Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2015, closing a stake of 50 shares — an estimated $23K sold.

Karp Capital Management first reported a position in REGN in Q2 2015 and held it in 2 quarters. The position peaked at $26K in Q2 2015. 577 funds tracked by Wall St. Rank hold REGN as of Q4 2015.

  • Karp Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Karp Capital Management sold 50 Regeneron Pharmaceuticals shares in Q4 2015, an estimated $23K.
  • Karp Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Karp Capital Management's Regeneron Pharmaceuticals position peaked at $26K in Q2 2015.
  • 577 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2015.

Based on Karp Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.